Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board
28 March 2023 - 11:30PM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, today announced the appointment of
Jeff Karp, Ph.D. to Eterna’s Scientific Advisory Board.
Matt Angel, Ph.D., Chief Executive Officer and
President of Eterna, commented, “Jeff is a world-class expert in
drug delivery and cell therapeutics with a successful track record
as an entrepreneur whose innovations have spurred numerous
biomedical products and companies. We are honored to welcome him to
Eterna’s Scientific Advisory Board as we advance toward our goal of
becoming a central resource of technology, expertise, and
intellectual property to support the development of next-generation
mRNA-based therapeutic products.”
Jeff Karp, Ph.D., added, “mRNA cell engineering has
the potential to make a significant impact across many therapeutic
areas and has been an active area of my research for over a decade.
I look forward to joining this experienced advisory board and
sharing insights with the management team as they work to develop
and deploy this powerful platform.”
Dr. Karp is the Distinguished Chair in Clinical
Anesthesiology, Perioperative and Pain Medicine at Brigham and
Women’s Hospital and Professor of Anesthesia at Harvard Medical
School in Boston. He is also a principal faculty member at the
Harvard Stem Cell Institute, and an affiliate faculty member at the
Broad Institute and at the Harvard-MIT Division of Health Sciences
and Technology. Dr. Karp was elected a fellow of the National
Academy of Inventors, Royal Society of Chemistry, American
Institute for Medical and Biological Engineering’s College of
Fellows, Biomedical Engineering Society (BMES), and the Canadian
Academy of Engineering. He has published over 125 peer-reviewed
papers with more than 30,000 citations. Several technologies
developed in his lab have led to multiple products currently in
development or on the market, and to the launch of ten companies.
Dr. Karp has received more than 50 awards and honors. Most
recently, he received the Clemson Award for Applied Research, the
highest award for innovation from the Society for Biomaterials.
Boston Magazine recognized Dr. Karp as one of 11 Boston Doctors
Making Medical Breakthroughs and the Boston Business Journal
recognized him as a Champion in Healthcare Innovation. MIT
Technology Review magazine also recognized Dr. Karp as being one of
the top innovators in the world in its “TR35” list, and three
members from his laboratory have subsequently received this award.
His work has been selected by Popular Mechanics as one of the Top
20 New Biotech Breakthroughs that Will Change Medicine.
About Eterna TherapeuticsEterna
Therapeutics is a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines. Eterna has in-licensed a portfolio
of over 100 patents covering key mRNA cell engineering
technologies, including technologies for mRNA cell reprogramming,
mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing
proteins, and the ToRNAdo™ mRNA delivery system from Factor
Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of
Factor Bioscience. For more information, please visit
www.eternatx.com.Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are intended to be covered by the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are any statements that are not
statements of historical fact and may be identified by terminology
such as “believe,” “could,” “estimate,” “anticipate,” “expect,”
“plan,” “possible,” “potential,” “project,” “will” or other similar
words and the negatives of such words. Forward-looking statements
are based on current beliefs and assumptions that are subject to
risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
stated or implied in any forward-looking statement as a result of
various factors, including, but not limited to, uncertainties
related to: (i) the evolution of Eterna’s business model into a
platform company focused on mRNA, iPS cell and gene editing
technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; and (v) Eterna ’s ability to obtain
regulatory approvals of its products for commercialization. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2022, as well as under similar headings in
Eterna’s subsequently filed Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K.
Investor Relations
Contact:investors@eternatx.com
Media
Contact:EternaPR@westwicke.com
Source: Eterna Therapeutics Inc.
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Mar 2024 to Mar 2024
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Mar 2023 to Mar 2024